🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

📍Mafalda Oliveira : "Si todos los implicados en el abordaje del cáncer afrontamos estos retos en los próximos años, estaremos más cerca de la ecuación ideal y de hacer de la investigación académica un aliado clave de la innovación oncológica" vía iSanidad 👀artículo completo👇

Check out this recently published paper on #CHEK2-related #BreastCancer and the real-world challenges associated with it. 👉pubmed.ncbi.nlm.nih.gov/39966186/ Luiza Weis - Oncologia Brittany Bychkovsky, MD Adela Rodríguez Hernández Romualdo Barroso, MD PhD

Looks interesting and worthy of a "slow resding" pubmed.ncbi.nlm.nih.gov/39777474/

The 19th St. Gallen Conference took place this week in Vienna. Nearly 80 expert panelists voted on key debated topics in breast oncology, selected by Harold J. Burstein, MD, PhD, FASCO & G Curigliano MD PhD. Here’s 10 key results from the #SGBCC2025 consensus voting, divided by topic/breast cancer subtype.

Si eres residente de #oncología al V año #R5 te interesa la investigación y te gusta o te gustaría prevalentemente enfocarte en cáncer de mama, SOLTI #cancerresearch es tu lugar y #SOLTIYoung tu segunda casa. Podrás acceder a tutorías, becas y programas educativos por y para jóvenes. Súmate!

Te interesa la Oncología Médica? Ven el día 20 de marzo a las puertas abiertas del ⁦Hospital Clínic⁩ a conocer nuestro servicio o contáctanos para cualquier duda! #MIR #MIR2025 ⁦⁩ #residentsCLÍNIC #CLÍNIC #medicina #residentes #oncología #oncologíamédica

📢 Our comprehensive review on post-progression treatment strategies after CDK4/6 inhibitor in HR+/HER2− MBC is now published in Cancer Treatment Reviews. Grateful to Deniz Can Guven and Sercan Aksoy, MD for their invaluable mentorship and support 🙏🏻 👉doi.org/10.1016/j.ctrv…

Additional proposed mechanisms to explain T-DXd efficacy… from preclinical studies. Out today on Nature Communications nature.com/articles/s4146…

Now out our work on a large cohort (n=859‼️) of patients with #breastcancer and leptomeningeal metastases🧠 Happy to share that our work results from an international collaboration of young oncologists committed to advance cancer research👇🏻 OncoAlert thebreastonline.com/article/S0960-…

Great time in Basel to address with Roche physicians’ and patients’ needs to improve the collaboration on clinical trials. Thanks for inviting me!

Promising chemo-free option for HR+/HER2+ metastatic breast cancer: our phase 2a study shows zanidatamab + palbociclib + fulvestrant is safe and active in heavily pretreated patients. Now published in The Lancet Oncology. doi.org/10.1016/S1470-… INCLIVA GVA Sanitat

Hello from Munich! #ESMOBreast25, here we go

Sara Tolaney from Dana-Farber’s Breast Oncology Center reviews a rainbow of novel treatment options becoming available for HR+/HER2- mBC over the past yrs (& many upcoming approvals over the next year). New challenges: optimizing their sequence & selecting control arms #ESMOAmbassadors #ESMOBreast25

Proffered paper session at #ESMOBreast25 with final results from #APHINITY trial at 11.3 years median follow-up addressing the addition of adjuvant #pertuzumab to #trastuzumab plus #chemotherapy in patients with #HER2+ ESMO - Eur. Oncology #ESMOAmbassadors OncoAlert #bcsm Evandro de Azambuja, MD, PhD

One of my favorite posters of #ESMOBreast25, addressing an important question: 👉What is the outcome of post-T-DXd treatments in HER2+ mBC? Does T-DXd-induced HER2 downregulation impair the activity of subsequent T-DM1? TKIs? Chemo? Answer below 1/4

Cristina Saura does an outstanding job discussing iza-bren, zani, and tucatinib +H #ESMOBreast25 ESMO - Eur. Oncology OncoAlert

We wrap up a new edition of #ESMOBreast25 filled with science, connections, hard work, and EXCITEMENT! From oral presentations like PROMETEO, posters like VALENTINE or CDK-PREDICT, and collaborations such as PROCURE and DEFINITIVE, to reunions with colleagues and meetings about

Today was a special one. For the first time, I served as a member of a PhD thesis committee. It was an incredibly meaningful experience, both my mother and father have done this for many years! (Hello Dad, I hope you could somehow see me from wherever you are now, and be proud).

Most viewed this week from JAMA Oncology: While phase 3 oncology trials frequently report success based on alternative endpoints, actual enhancements in overall survival and quality of life are uncommon. ja.ma/4dVJAU8

Important reading for all clinical trialists: always be aware of (and transparent about!) the event „classification“ for your study endpoints. Great work by ABCSG led by Dominik Hlauschek! doi.org/10.1016/j.esmo… MedUni Wien